The state of Missouri currently has 364 active clinical trials seeking participants for Cancer research studies. These trials are conducted in various cities, including Saint Louis, Kansas City, St. Louis and Springfield.
Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry
Recruiting
PROGECT is a registry for patients with Triple Negative breast cancer (TNBC) or patients who have an identified germline mutations (such as a mutation on the BRCA1 or BRCA2 genes).
Gender:
ALL
Ages:
All
Trial Updated:
05/08/2023
Locations: Centerpoint Regional Medical Center, Independence, Missouri +5 locations
Conditions: Breast Cancer, Hereditary Breast and Ovarian Cancer
Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer
Recruiting
This study evaluates the safety and efficacy of sacituzumab govitecan plus alpelisib for treatment of metastatic or locally recurrent HER2-negative breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2023
Locations: The University of Kansas Cancer Center - North Kansas City Hospital, Kansas City, Missouri +2 locations
Conditions: Breast Cancer
Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors
Recruiting
The purpose of this study is to evaluate the safety, tolerability, and preliminary activity of SQ3370 in patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/08/2023
Locations: Washington University in St. Louis, Saint Louis, Missouri
Conditions: Cancer
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer
Recruiting
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy. Condition or disease: Breast Cancer Intervention/treatment: Drug: Gedatolisib Drug: Palbociclib Drug: Fulvestrant Drug: Alpelisib Phase 3
Gender:
All
Ages:
18 years and above
Trial Updated:
08/02/2022
Locations: University of Missouri Health Care, Columbia, Missouri
Conditions: Breast Cancer